Karen Laky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karen Laky has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Justin Lack
Collaborative Bioinformatics Resource, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
2 shared publications- Pamela A. Frischmeyer-Guerrerio
Laboratory of Allergic Diseases National Institute of Allergy and Infectious Diseases, NIH Bethesda Maryland USA
2 shared publications - Ajinkya R. Limkar
Medical Scientist Training Program, University of Wisconsin-Madison, Madison, WI
1 shared publication - Ana Olivera
Mast Cell Biology Section Laboratory of Allergic Diseases National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland USA
1 shared publication - Anthony L. Guerrerio
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
1 shared publication - Benjamin Schwarz
Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
1 shared publication
Latest Publications
- Open Access
Time‐Resolved Multi‐Omics Identify Biomarkers of Immediate Reactions to mRNA Vaccination
Background: Systemic allergic reactions (sARs) after vaccination are life‐threatening and can erode vaccine confidence. Distinguishing sARs from immunization stress‐related responses (ISRRs), which require different management, remains a clinical challenge. We sought to identify biomarkers distinguishing sARs from ISRRs, characterize their early immune and metabolic pathways, and determine whether immediate reactions alter subsequent vaccine‐induced immunity. Methods: We profiled samples from a double‐blind, placebo‐controlled BNT162b2 re‐vaccination trial (NCT04977479) in individuals with allergic reactions to a first mRNA vaccine dose. Whole‐blood transcriptomics, plasma proteomics and metabolomics, blood counts, and flow cytometry were assessed 0.5–24 h after the second dose, booster, and placebo. Anti‐spike antibodies were measured longitudinally; anti‐nucleocapsid antibodies identified intercurrent infection. Results: Interferon and antiviral transcriptional programs 24 h post‐vaccination and subsequent anti‐spike antibody responses were preserved across reaction groups. However, longer‐than‐recommended intervals between first and second doses were associated with lower antibody titers. In participants with mild to no reactions, neutrophil activation and degranulation signatures peaked at 6 h; these responses were blunted in ISRRs despite comparable early neutrophil mobilization. ISRRs were also marked by a stress‐metabolic state with early norepinephrine increases; sustained bisphosphoglycerate and 2/3‐phosphoglycerate elevations; reduced basophil activation/recruitment markers (CD63, CD193); downregulation of basophil‐associated transcripts (CPA3, HDC, MS4A3); and upregulation of stress‐linked genes (OTOF, SNORD3). sARs showed opposite metabolic trajectories and trended toward early neutrophil CD63 upregulation. Conclusion: Time‐resolved immune and metabolic signatures identified candidate biomarkers distinguishing ISRRs from sARs, with implications for diagnosis, management, and vaccine adherence. Notably, reactions did not impair vaccine‐elicited antiviral responses or humoral immunity.
Open AccessTime‐Resolved Multi‐Omics Identify Biomarkers of Immediate Reactions to mRNA Vaccination
Background: Systemic allergic reactions (sARs) after vaccination are life‐threatening and can erode vaccine confidence. Distinguishing sARs from immunization stress‐related responses (ISRRs), which require different management, remains a clinical challenge. We sought to identify biomarkers distinguishing sARs from ISRRs, characterize their early immune and metabolic pathways, and determine whether immediate reactions alter subsequent vaccine‐induced immunity. Methods: We profiled samples from a double‐blind, placebo‐controlled BNT162b2 re‐vaccination trial (NCT04977479) in individuals with allergic reactions to a first mRNA vaccine dose. Whole‐blood transcriptomics, plasma proteomics and metabolomics, blood counts, and flow cytometry were assessed 0.5–24 h after the second dose, booster, and placebo. Anti‐spike antibodies were measured longitudinally; anti‐nucleocapsid antibodies identified intercurrent infection. Results: Interferon and antiviral transcriptional programs 24 h post‐vaccination and subsequent anti‐spike antibody responses were preserved across reaction groups. However, longer‐than‐recommended intervals between first and second doses were associated with lower antibody titers. In participants with mild to no reactions, neutrophil activation and degranulation signatures peaked at 6 h; these responses were blunted in ISRRs despite comparable early neutrophil mobilization. ISRRs were also marked by a stress‐metabolic state with early norepinephrine increases; sustained bisphosphoglycerate and 2/3‐phosphoglycerate elevations; reduced basophil activation/recruitment markers (CD63, CD193); downregulation of basophil‐associated transcripts (CPA3, HDC, MS4A3); and upregulation of stress‐linked genes (OTOF, SNORD3). sARs showed opposite metabolic trajectories and trended toward early neutrophil CD63 upregulation. Conclusion: Time‐resolved immune and metabolic signatures identified candidate biomarkers distinguishing ISRRs from sARs, with implications for diagnosis, management, and vaccine adherence. Notably, reactions did not impair vaccine‐elicited antiviral responses or humoral immunity.
- 19 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (91) , eadg8691
TGFβ prevents IgE-mediated allergic disease by restraining T follicular helper 2 differentiation
Allergic diseases are common, affecting more than 20% of the population. Genetic variants in the TGFβ pathway are strongly associated with atopy. To interrogate the mechanisms underlying this association, we examined patients and mice with Loeys-Dietz syndrome (LDS) who harbor missense mutations in the kinase domain of TGFΒR1/2 . We demonstrate that LDS mutations lead to reduced TGFβ signaling and elevated total and allergen-specific IgE, despite the presence of wild-type T regulatory cells in a chimera model. Germinal center activity was enhanced in LDS and characterized by a selective increase in type 2 follicular helper T cells (T FH 2). Expression of Pik3cg was increased in LDS T FH cells and associated with reduced levels of the transcriptional repressor SnoN. PI3Kγ/mTOR signaling in LDS naïve CD4 + T cells was elevated after T cell receptor cross-linking, and pharmacologic inhibition of PI3Kγ or mTOR prevented exaggerated T FH 2 and antigen-specific IgE responses after oral antigen exposure in an adoptive transfer model. Naïve CD4 + T cells from nonsyndromic allergic individuals also displayed decreased TGFβ signaling, suggesting that our mechanistic discoveries may be broadly relevant to allergic patients in general. Thus, TGFβ plays a conserved, T cell–intrinsic, and nonredundant role in restraining T FH 2 development via the PI3Kγ/mTOR pathway and thereby protects against allergic disease.
- 19 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (91) , eadg8691
TGFβ prevents IgE-mediated allergic disease by restraining T follicular helper 2 differentiation
Allergic diseases are common, affecting more than 20% of the population. Genetic variants in the TGFβ pathway are strongly associated with atopy. To interrogate the mechanisms underlying this association, we examined patients and mice with Loeys-Dietz syndrome (LDS) who harbor missense mutations in the kinase domain of TGFΒR1/2 . We demonstrate that LDS mutations lead to reduced TGFβ signaling and elevated total and allergen-specific IgE, despite the presence of wild-type T regulatory cells in a chimera model. Germinal center activity was enhanced in LDS and characterized by a selective increase in type 2 follicular helper T cells (T FH 2). Expression of Pik3cg was increased in LDS T FH cells and associated with reduced levels of the transcriptional repressor SnoN. PI3Kγ/mTOR signaling in LDS naïve CD4 + T cells was elevated after T cell receptor cross-linking, and pharmacologic inhibition of PI3Kγ or mTOR prevented exaggerated T FH 2 and antigen-specific IgE responses after oral antigen exposure in an adoptive transfer model. Naïve CD4 + T cells from nonsyndromic allergic individuals also displayed decreased TGFβ signaling, suggesting that our mechanistic discoveries may be broadly relevant to allergic patients in general. Thus, TGFβ plays a conserved, T cell–intrinsic, and nonredundant role in restraining T FH 2 development via the PI3Kγ/mTOR pathway and thereby protects against allergic disease.
- 13 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (79) , eabp9940
Epithelial-intrinsic defects in TGFβR signaling drive local allergic inflammation manifesting as eosinophilic esophagitis
Allergic diseases are a global health challenge. Individuals harboring loss-of-function variants in transforming growth factor–β receptor (TGFβR) genes have an increased prevalence of allergic disorders, including eosinophilic esophagitis. Allergic diseases typically localize to mucosal barriers, implicating epithelial dysfunction as a cardinal feature of allergic disease. Here, we describe an essential role for TGFβ in the control of tissue-specific immune homeostasis that provides mechanistic insight into these clinical associations. Mice expressing a TGFβR1 loss-of-function variant identified in atopic patients spontaneously develop disease that clinically, immunologically, histologically, and transcriptionally recapitulates eosinophilic esophagitis. In vivo and in vitro, TGFβR1 variant–expressing epithelial cells are hyperproliferative, fail to differentiate properly, and overexpress innate proinflammatory mediators, which persist in the absence of lymphocytes or external allergens. Together, our results support the concept that TGFβ plays a fundamental, nonredundant, epithelial cell–intrinsic role in controlling tissue-specific allergic inflammation that is independent of its role in adaptive immunity.
- 13 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (79) , eabp9940
Epithelial-intrinsic defects in TGFβR signaling drive local allergic inflammation manifesting as eosinophilic esophagitis
Allergic diseases are a global health challenge. Individuals harboring loss-of-function variants in transforming growth factor–β receptor (TGFβR) genes have an increased prevalence of allergic disorders, including eosinophilic esophagitis. Allergic diseases typically localize to mucosal barriers, implicating epithelial dysfunction as a cardinal feature of allergic disease. Here, we describe an essential role for TGFβ in the control of tissue-specific immune homeostasis that provides mechanistic insight into these clinical associations. Mice expressing a TGFβR1 loss-of-function variant identified in atopic patients spontaneously develop disease that clinically, immunologically, histologically, and transcriptionally recapitulates eosinophilic esophagitis. In vivo and in vitro, TGFβR1 variant–expressing epithelial cells are hyperproliferative, fail to differentiate properly, and overexpress innate proinflammatory mediators, which persist in the absence of lymphocytes or external allergens. Together, our results support the concept that TGFβ plays a fundamental, nonredundant, epithelial cell–intrinsic role in controlling tissue-specific allergic inflammation that is independent of its role in adaptive immunity.
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 4 (7) , 415-419
Bone Marrow–Derived Dendritic Cell Cultures from RAG−/− Mice Include IFN-γ–Producing NK Cells
Dendritic cells (DCs) play a key role in the initiation of an immune response and are known as “professional” APCs because of their ability to activate naive T cells. A widely used method to generate DCs in vitro is to culture bone marrow (BM) cells or blood monocytes in the presence of GM-CSF and IL-4. In this study, we show that a small population of NK cells residing in the BM of RAG−/−, but not RAG−/− γc chain−/− mice, remain in the DC culture and is the source of IFN-γ produced after stimulation with LPS. These cells, which may represent early promoters of LPS-induced responses, have to be taken into account when interpreting experiments using BM-derived DCs.
- 1 July 2020
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 4 (7) , 415-419
Open AccessBone Marrow–Derived Dendritic Cell Cultures from RAG−/− Mice Include IFN-γ–Producing NK Cells
Dendritic cells (DCs) play a key role in the initiation of an immune response and are known as “professional” APCs because of their ability to activate naive T cells. A widely used method to generate DCs in vitro is to culture bone marrow (BM) cells or blood monocytes in the presence of GM-CSF and IL-4. In this study, we show that a small population of NK cells residing in the BM of RAG−/−, but not RAG−/− γc chain−/− mice, remain in the DC culture and is the source of IFN-γ produced after stimulation with LPS. These cells, which may represent early promoters of LPS-induced responses, have to be taken into account when interpreting experiments using BM-derived DCs.